Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Hydrogen Peroxide→

Hydrogen Peroxide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7722-84-1
Molecular formula
H2O2
Molecular weight
34.015 g/mol
Drug class
Oxidising antiseptictopical antimicrobial agent
Mechanism of action
Releases reactive oxygen species that oxidise microbial cellular components. The oxidative action is non-selective and can also affect host tissue at higher concentrations or with prolonged exposure.
Indications / reported uses
  • General-purpose topical antiseptic for first-aid treatment of minor cuts and abrasions with suitable low-concentration formulations.

Sources: https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=professional&setid=f6d677b8-fa89-4efb-984a-fd98e3e590e8 · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/a-101-topical-solution

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Hydrogen Peroxide Environmental Risk Assessment (ERA) (the Hydrogen Peroxide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.